Hetal Kocinsky, M.D.

Dr. Hetal Kocinsky serves as Jade Biosciences’ Chief Medical Officer. Dr. Kocinsky brings deep expertise in drug development, having led clinical programs from early-stage research to regulatory approvals across multiple therapeutic areas. Most recently, she served as Vice President of Translational Medicine at Chinook Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company acquired by Novartis AG in August 2023. At Chinook, she oversaw the clinical elements of an NDA submission and led early clinical development, clinical pharmacology, toxicology, and biomarker functions. 

Before Chinook, Dr. Kocinsky held leadership roles at Apellis Pharmaceuticals, where she served as Executive Medical Director and Senior Medical Director, leading clinical teams in neurology, hematology, and nephrology from Phase 2 through post-marketing development. From 2012 to 2018, she held roles of increasing responsibility at Achillion Pharmaceuticals, most recently as Executive Medical Director, contributing initially to clinical programs in hepatology which were subsequently partnered with Janssen Pharmaceuticals, and then programs in nephrology and hematology which were later acquired by Alexion Pharmaceuticals. 

A board-certified pediatric nephrologist, Dr. Kocinsky also spent time as an Assistant Professor at Yale University School of Medicine in the Department of Pediatric Nephrology. She earned her B.A. from Columbia College, Columbia University, and her M.D. from UT Southwestern Medical Center. Dr. Kocinsky completed her residency in Pediatrics at St. Christopher’s Hospital for Children and a fellowship in Pediatric Nephrology at Yale University School of Medicine.